- Home
- SGLY vs TLPH Comparison
SGLY vs TLPH Comparison
Compare SGLY & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGLY
- TLPH
- Stock Information
- Founded
- SGLY 2001
- TLPH 2005
- Country
- SGLY United States
- TLPH United States
- Employees
- SGLY N/A
- TLPH N/A
- Industry
- SGLY
- TLPH Biotechnology: Pharmaceutical Preparations
- Sector
- SGLY
- TLPH Health Care
- Exchange
- SGLY Nasdaq
- TLPH Nasdaq
- Market Cap
- SGLY 15.9M
- TLPH 13.4M
- IPO Year
- SGLY 2008
- TLPH 2011
- Fundamental
- Price
- SGLY $1.65
- TLPH $0.79
- Analyst Decision
- SGLY
- TLPH Strong Buy
- Analyst Count
- SGLY 0
- TLPH 2
- Target Price
- SGLY N/A
- TLPH $4.50
- AVG Volume (30 Days)
- SGLY 153.3K
- TLPH 69.9K
- Earning Date
- SGLY 11-11-2024
- TLPH 11-06-2024
- Dividend Yield
- SGLY N/A
- TLPH N/A
- EPS Growth
- SGLY N/A
- TLPH N/A
- EPS
- SGLY N/A
- TLPH N/A
- Revenue
- SGLY $3,370,424.00
- TLPH $398,000.00
- Revenue This Year
- SGLY N/A
- TLPH N/A
- Revenue Next Year
- SGLY N/A
- TLPH N/A
- P/E Ratio
- SGLY N/A
- TLPH N/A
- Revenue Growth
- SGLY N/A
- TLPH 57.31
- 52 Week Low
- SGLY $1.27
- TLPH $0.43
- 52 Week High
- SGLY $7.65
- TLPH $1.61
- Technical
- Relative Strength Index (RSI)
- SGLY 41.57
- TLPH 40.28
- Support Level
- SGLY $1.55
- TLPH $0.76
- Resistance Level
- SGLY $1.79
- TLPH $0.83
- Average True Range (ATR)
- SGLY 0.19
- TLPH 0.08
- MACD
- SGLY 0.10
- TLPH -0.00
- Stochastic Oscillator
- SGLY 61.29
- TLPH 32.00
About SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.